Biomechanical and biological features of hyaluronic acid in combination with chondroitin and platelet rich plasma for regenerative medicine applications.

IF 4.8 3区 工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Frontiers in Bioengineering and Biotechnology Pub Date : 2025-10-07 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1607469
Valentina Vassallo, Celeste Di Meo, Antonella D'Agostino, Annalisa La Gatta, Donatella Cimini, Giuseppe Toro, Giovanni Iolascon, Maddalena Mastrogiacomo, Chiara Schiraldi
{"title":"Biomechanical and biological features of hyaluronic acid in combination with chondroitin and platelet rich plasma for regenerative medicine applications.","authors":"Valentina Vassallo, Celeste Di Meo, Antonella D'Agostino, Annalisa La Gatta, Donatella Cimini, Giuseppe Toro, Giovanni Iolascon, Maddalena Mastrogiacomo, Chiara Schiraldi","doi":"10.3389/fbioe.2025.1607469","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, one of the most common treatments for osteoarthritis (OA) is viscosupplementation using intra-articular injectable gels, often based on glycosaminoglycans (GAGs), specifically hyaluronic acid (HA) and, in some cases, chondroitin sulfate (CS). Recently, the potential benefits of pharma-grade biofermentative unsulfated chondroitin (BC) have been established, particularly when combined with high molecular weight hyaluronan (HHA). Beyond GAGs, platelet-rich plasma (PRP) has also been reported to have beneficial effects, although many clinical studies lack proper control groups. The aim of this study was to perform a comparative analysis of injectable formulations based on BC combined with HHA (HHA/BC), both alone and in combination with PRP, to evaluate their rheological and biological properties. Flow curves and mechanical spectra of HHA/BC and HHA/BC+PRP were obtained to assess their viscoelastic behavior in relation to synovial fluid characteristics. Then, these two formulations were tested on human chondrocytes isolated from OA joints to investigate their functional role <i>in vitro</i> on specific biochemical pathways. Additionally, a chondrocyte monolayer scratch assay was performed to evaluate their repair potential using time-lapse video-microscopy. Finally, chondrocytes were cultured in GAG-based gels on transwell inserts for 14 days to mimic a 3D-like <i>in vitro</i> environment. HHA/BC+PRP exhibited a consistent rheological profile, supporting its potential application in intra-articular injections. Furthermore, the maintenance of cell phenotype was confirmed through the analysis of collagen type 2A1 (COL2A1) and aggrecan (ACAN) expression. The addition of PRP further enhanced the ability of GAGs to reduce specific pro-inflammatory and degradative OA-related markers (e.g., interleukin IL-6, NF-κB, metalloprotease MMP-13, and cartilage oligomeric matrix protein COMP-2). Both HHA/BC and HHA/BC+PRP similarly prompted scratch repair. Overall, these outcomes provide deeper insights into the biochemical and biological properties of these innovative injectable formulations, highlighting their potential application in OA management.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1607469"},"PeriodicalIF":4.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12537726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1607469","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, one of the most common treatments for osteoarthritis (OA) is viscosupplementation using intra-articular injectable gels, often based on glycosaminoglycans (GAGs), specifically hyaluronic acid (HA) and, in some cases, chondroitin sulfate (CS). Recently, the potential benefits of pharma-grade biofermentative unsulfated chondroitin (BC) have been established, particularly when combined with high molecular weight hyaluronan (HHA). Beyond GAGs, platelet-rich plasma (PRP) has also been reported to have beneficial effects, although many clinical studies lack proper control groups. The aim of this study was to perform a comparative analysis of injectable formulations based on BC combined with HHA (HHA/BC), both alone and in combination with PRP, to evaluate their rheological and biological properties. Flow curves and mechanical spectra of HHA/BC and HHA/BC+PRP were obtained to assess their viscoelastic behavior in relation to synovial fluid characteristics. Then, these two formulations were tested on human chondrocytes isolated from OA joints to investigate their functional role in vitro on specific biochemical pathways. Additionally, a chondrocyte monolayer scratch assay was performed to evaluate their repair potential using time-lapse video-microscopy. Finally, chondrocytes were cultured in GAG-based gels on transwell inserts for 14 days to mimic a 3D-like in vitro environment. HHA/BC+PRP exhibited a consistent rheological profile, supporting its potential application in intra-articular injections. Furthermore, the maintenance of cell phenotype was confirmed through the analysis of collagen type 2A1 (COL2A1) and aggrecan (ACAN) expression. The addition of PRP further enhanced the ability of GAGs to reduce specific pro-inflammatory and degradative OA-related markers (e.g., interleukin IL-6, NF-κB, metalloprotease MMP-13, and cartilage oligomeric matrix protein COMP-2). Both HHA/BC and HHA/BC+PRP similarly prompted scratch repair. Overall, these outcomes provide deeper insights into the biochemical and biological properties of these innovative injectable formulations, highlighting their potential application in OA management.

Abstract Image

Abstract Image

Abstract Image

透明质酸与软骨素和富血小板血浆联合应用于再生医学的生物力学和生物学特性。
目前,骨关节炎(OA)最常见的治疗方法之一是使用关节内注射凝胶补充粘,通常基于糖胺聚糖(GAGs),特别是透明质酸(HA),在某些情况下,硫酸软骨素(CS)。最近,制药级生物发酵无硫酸软骨素(BC)的潜在益处已经得到证实,特别是与高分子量透明质酸(HHA)结合使用时。除了GAGs,富血小板血浆(PRP)也被报道具有有益作用,尽管许多临床研究缺乏适当的对照组。本研究的目的是对基于BC联合HHA (HHA/BC)的注射制剂进行比较分析,无论是单独使用还是与PRP联合使用,以评估其流变学和生物学特性。获得HHA/BC和HHA/BC+PRP的流动曲线和力学谱,以评估其与滑液特性的粘弹性行为。然后,在OA关节分离的人软骨细胞上测试这两种配方,以研究它们在体外对特定生化途径的功能作用。此外,使用延时视频显微镜进行软骨细胞单层划痕试验以评估其修复潜力。最后,软骨细胞在transwell插入物上的gag凝胶中培养14天,以模拟3d样的体外环境。HHA/BC+PRP表现出一致的流变学特征,支持其在关节内注射中的潜在应用。此外,通过分析胶原型2A1 (COL2A1)和聚集蛋白(ACAN)的表达,证实了细胞表型的维持。PRP的加入进一步增强了GAGs降低特异性促炎和降解性oa相关标志物(如白细胞介素IL-6、NF-κB、金属蛋白酶MMP-13和软骨寡聚基质蛋白COMP-2)的能力。HHA/BC和HHA/BC+PRP同样促进划痕修复。总的来说,这些结果为这些创新注射制剂的生化和生物学特性提供了更深入的见解,突出了它们在OA管理中的潜在应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Bioengineering and Biotechnology
Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering
CiteScore
8.30
自引率
5.30%
发文量
2270
审稿时长
12 weeks
期刊介绍: The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信